Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2025 09:00 ET | Source: BioAge Labs, Inc.

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor...
May 27, 2025 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...
May 06, 2025 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands...
March 20, 2025 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships...
February 20, 2025 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
January 28, 2025 09:00 ET | Source: BioAge Labs, Inc.

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of...
December 18, 2024 09:00 ET | Source: BioAge Labs, Inc.

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to...
December 06, 2024 16:35 ET | Source: BioAge Labs, Inc.

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated...
December 05, 2024 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
November 21, 2024 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...